Embryonic stem cell transplantation for the treatment of myocardial infarction: Immune privilege or rejection

作者：Yuan Xin; Zhang Hao^*; Wei Ying Jie; Hu Sheng Shou

来源：Transplant Immunology, 2007, 18(2): 88-93.

DOI：10.1016/j.trim.2007.05.003

• embryonic stem cell
• myocardial infarction
• immunogenicity

Stem cell transplantation (SCT) has emerged to be an appealing tool for repair medicine. In the treatment of ischemic heart diseases, SCT will be of great help because it is capable of replacing sear with new myocardial tissue. Among the many candidate cell lines for SCT, embryonic stem cells (ESCs) have their unique advantages. However, the controversy about the host immune attack and the transplanted ESCs or their derivatives transplanted into ischemic heart still existed. In this review, the immune properties of ESCs and ESC-derived cardiomyocytes and possible mechanisms were discussed; furthermore, the prevention strategies against potential immune responses were also identified.

• 出版日期2007-11
• 单位中国医学科学院阜外医院